DrugPatentWatch Database Preview
Investigational Drug Information for Ganitumab
Email this page to a colleague
What is the development status for investigational drug Ganitumab?
Ganitumab is an investigational drug.
There have been 15 clinical trials for Ganitumab.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 8th 2014.
The most common disease conditions in clinical trials are Neoplasms, Colorectal Neoplasms, and Neoplasm Metastasis. The leading clinical trial sponsors are Amgen, National Cancer Institute (NCI), and NantCell, Inc.
There are twelve US patents protecting this investigational drug and two hundred and fifty-six international patents.
Summary for Ganitumab
| US Patents | 12 |
| International Patents | 256 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2014-12-08) |
| Vendors | 0 |
Recent Clinical Trials for Ganitumab
| Title | Sponsor | Phase |
|---|---|---|
| Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma | National Cancer Institute (NCI) | Early Phase 1 |
| Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma | M.D. Anderson Cancer Center | Early Phase 1 |
| Palbociclib + Ganitumab In Ewing Sarcoma | 1 Million 4 Anna Foundation | Phase 2 |
Clinical Trial Summary for Ganitumab
Top disease conditions for Ganitumab
Top clinical trial sponsors for Ganitumab
US Patents for Ganitumab
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ganitumab | ⤷ Sign up for a Free Trial | Multispecific constructs | AbbVie Stemcentrx LLC (North Chicago, IL) | ⤷ Sign up for a Free Trial |
| Ganitumab | ⤷ Sign up for a Free Trial | Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein | CureVac AG (Tubingen, DE) | ⤷ Sign up for a Free Trial |
| Ganitumab | ⤷ Sign up for a Free Trial | Binding-triggered transcriptional switches and methods of use thereof | The Regents of the University of California (Oakland, CA) | ⤷ Sign up for a Free Trial |
| Ganitumab | ⤷ Sign up for a Free Trial | Curcuphenol compounds for increasing MHC-I expression | CAVA HEALTHCARE INC. (CA) | ⤷ Sign up for a Free Trial |
| Ganitumab | ⤷ Sign up for a Free Trial | P97 fragments with transfer activity | biOasis Technologies, Inc. (Vancouver, British Columbia, unknown) | ⤷ Sign up for a Free Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ganitumab
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ganitumab | Canada | CA2900764 | 2033-02-08 | ⤷ Sign up for a Free Trial |
| Ganitumab | European Patent Office | EP2954056 | 2033-02-08 | ⤷ Sign up for a Free Trial |
| Ganitumab | Hong Kong | HK1218930 | 2033-02-08 | ⤷ Sign up for a Free Trial |
| Ganitumab | Japan | JP2016509014 | 2033-02-08 | ⤷ Sign up for a Free Trial |
| Ganitumab | World Intellectual Property Organization (WIPO) | WO2014124326 | 2033-02-08 | ⤷ Sign up for a Free Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
